Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/16474
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
Álvaro-Gracia, José M | Sanchez-Piedra, Carlos Alberto ISCIII | Culqui, Dante | Rosello, Rosa | Garcia-Dorta, Alicia | Campos, Cristina | Manrique-Arija, Sara | Ruiz-Montesinos, Dolores | Ros-Vilamajo, Inmaculada | Rodríguez-Lozano, Carlos | Freire-González, Mercedes | Caliz, Rafael | Bohorquez, Cristina | Mateo Soria, Lourdes | Busquets, Noemí | Castrejon, Isabel | Sánchez-Alonso, Fernando | González-Dávila, Enrique | Diaz-Gonzalez, Federico
RMD Open. 2023 Mar;9(1):e002936.
Objective: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. Patients and methods: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model. Results: The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i. Conclusion: COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.
Files in this item
- Supplementary1_EffectsCOVID-19 ...
- Supplementary material 1
- Supplementary2_EffectsCOVID-19 ...
- Supplementary material 2